Hemispherx Biopharma Aktie

Hemispherx Biopharma für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2PREX / ISIN: US00901B1052

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
19.09.2024 14:21:35

AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination

(RTTNews) - AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of late-stage pancreatic cancer. The combination therapy was generally well-tolerated with no severe adverse events or dose-limiting toxicities. The first cohort has now reached the pre-determined 6-month stability assessment timepoint and two of the three subjects remain stable.

AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company's lead product is a first-in-class investigational drug called Ampligen.

For More Such Health News, visit rttnews.com.

Nachrichten zu Hemispherx Biopharma Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Hemispherx Biopharma Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AstraZeneca PLC (spons. ADRs) 71,50 4,38% AstraZeneca PLC (spons. ADRs)
Hemispherx Biopharma Inc Registered Shs 0,07 -1,96% Hemispherx Biopharma Inc Registered Shs